Abstract
Summary. Administration of direct oral anticoagulants (DOACs) for the treatment of venous thrombotic events (VTE) or non-valvular atrial fibrillation (AF) is now standard of care and has demonstrated clinical efficacy and safety in numerous clinical studies. Usually these substances have lower overall mortality and less risk of cerebral hemorrhage, but depending on the substance and study, they are more likely to cause gastrointestinal bleeding than vitamin K antagonists (VKA), the medication that used to be standard for VTE and AF. Since DOACs have very short plasma elimination half-lives compared to VKA, for most bleeding events, expert opinions suggest that withdrawal of DOACs and supportive care will likely suffice to stop a bleeding episode. Because there is a bleeding risk associated with DOACs, reversal strategies may be needed if a patient receiving DOAC therapy bleeds during surgery or an invasive procedure. So far, idarucizumab has been the only available antidote that binds specifically to dabigatran and safely and quickly reverses its anticoagulant effects. Idarucizumab has no effects on anti Xa inhibitors or other anticoagulants. To date, treatment of serious, life-threatening bleeds in patients with anti-Xa-inhibitor has involved 4 factor prothrombin complex concentrates (PCC). PCC restores normal hemostasis laboratory values in most patients with major bleeding events after anti Xa inhibitor intake. Recently, the US Food and Drug Administration (FDA) approved andexanet alfa as the first specific antidote for the anti-Xa inhibitors apixaban and rivaroxaban. So far clinical experience with this substance and data comparing it with PCC are lacking. Currently ciraparantag is under investigation as a universal reversal agent for all DOACs and low molecular weight heparin as well. Because it is so broadly applicable, ciraparantag might be a good future option for the management of most bleeding complications under anticoagulant treatment. The aim of this review is to summarize recent study data and recommendations on nonspecific and specific DOAC reversal strategies and to present the current evidence.
References
1
EINSTEIN Investigators . Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010 Dec 23;363(26):2499–510.2
Agnelli G ,Buller HR ,Cohen A ,Curto M ,Gallus AS ,Johnson M , Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013 Aug 29;369(9):799–808.3
The Hokusai-VTE Investigators . Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. N Engl J Med 2013 Oct 10;369(15):406–15.4
Schulman S ,Kakkar AK ,Goldhaber SZ ,Schellong S ,Eriksson H ,Mismetti P , RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014 Feb 18;129(7):764–72.5
Ruff CT ,Giugliano RP ,Braunwald E ,Hoffman EB ,Deenadayalu N ,Ezekowitz MD , Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014 Mar 15;383(9921):955–62.6
Yeh CH ,Gross PL ,Weitz JI , Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood 2014;124:1020–8.7
Chan NC ,Eikelboom JW ,Weitz JI , Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants. Circ Res 2016;118:1409–24.8
Sherwood MW ,Nessel CC ,Hellkamp AS ,Mahaffey KW ,Piccini JP ,Suh EY , Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. J Am Coll Cardiol 2015;66:2271–81.9
Masahir I ,Sumiyoshi N ,Mika Y ,Nobuhiko T , Profiles of direct oral anticoagulants and clinical usage – dosage and dose regimen differences. J Intensive Care 2016;4:19.10
Schwarb H ,Tsakiris D , New Direct Oral Anticoagulants (DOAC) and Their Use Today. Dent J (Basel) 2016 Mar;4(1):5.11
Willet CK ,Morril AM , Use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence. Ther Clin Risk Manag. 2017;13:447–454.12
Heidbuchel A ,Verhamme P ,Alings M ,Antz M ,Hacke W ,Oldgren J , European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013 May;15(5):625–51.13
Vranckx P ,Valgimigli M ,Heidbuchel H , The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation. Arrhythm Electrophysiol Rev 2018 Mar;7(1):55–61.14
Glund S ,Moschetti V ,Norris S ,Stangier J ,Schmohl M ,van Ryn J , A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015;113:943–51.15
Glund S ,Stangier J ,Schmohl M ,Gansser D ,Norris S ,van Ryn J , Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015;386:680–90.16
Pollack CV ,Reilly PA ,van Ryn J ,Eikelboom J ,Stephan Glund , Idarucizumab for Dabigatran Reversal. N Engl J Med 2015;373:511–20.17
Baumann-Durschein F ,Gary T ,Raggam RB , Case Report: Biliary Pancreatitis With Acute Cholangitis in a Patient Under Anticoagulant Treatment With Dabigatran. EJIFCC 2017 Oct;28(3):233–236.18
Crowther M ,Crowther MA , Antidotes for novel oral anticoagulants: current status and future potential. Atheroscler Thromb Vasc Biol 2015;35:1736–45.19
Ghadimi K ,Dombrowski KE ,Levy JH ,Welsby IJ , Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. Expert Rev Hematol 2016;9:115–22.20
Siegal DM ,Curnutte JT ,Connolly SJ ,Lu G ,Conley PB ,Wiens BL , Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med 2015;373:2413–24.21
Conolly SJ ,Milling TJ ,Eikelboom JW ,Gibson CM ,Curnutte JT ,Gold A , Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. NEJM 2016;375:1131–41.22
Levy JH ,Douketis J ,Weitz JI , Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol. 2018;15(5):273–81.23
Kaatz S ,Bhansali H ,Gibbs J ,Lavender R ,Mahan CE ,Paje DG , Reversing factor Xa inhibitors – clinical utility of andexanet alfa. J Blood Med. 2017;8:141–9.24
Lu G ,Pine P ,Leeds JM ,DeGuzman F ,Pratikhya P ,Lin J , Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model. PLoS One. 2018;13(3).25
Sullivan DW Jr ,Gad SC ,Laulicht B ,Bakhru S ,Steiner S . Nonclinical Safety Assessment of PER977: A Small Molecule Reversal Agent for New Oral Anticoagulants and Heparins. Int J Toxicol 2015;34:208–17.26
Ansell JE ,Bakhru SH ,Laulicht BE ,Steiner SS ,Grosso MA ,Brown K , Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost 2017;117:238–45.27
Eerenberg ES ,Kamphuisen PW ,Sijpkens MK ,Meijers JC ,Buller HR ,Levi M , Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573–1579.28
Nagalla S ,Thomson L ,Oppong Y ,Bachman B ,Chervoneva I ,Kraft WK . Reversibility of apixaban anticoagulation with a four-factor pro-thrombin complex concentrate in healthy volunteers. Clin Transl Sci. 2016;9(3):176–180.29
Majeed A ,Ågren A ,Holmström M ,Bruzelius M ,Chaireti R ,Odeberg J , Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood 2017 Oct 12;130(15):1706–1712.30
Varadi K ,Tangada S ,Loeschberger M ,Montsch P ,Schrenk G ,Ewenstein B , Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA(®) in prophylactic therapy. Haemophilia 2016;22:615–24.31
Perzborn E ,Heitmeier S ,Laux V ,Buchmüller A , Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res 2014;133:671–81.32
Rinehart D ,Lockhart NR ,Hamilton LA ,Langdon JR ,Rowe AS , Management of apixaban-associated subdural hematoma: a case report on the use of factor eight inhibitor bypassing activity. Crit Care Med 2015 Jun;43(6).33
Steffel J ,Verhamme P ,Potpara TS ,Albaladejo P ,Antz M ,Desteghe L , The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39:1330–1393.